scholarly journals Commentary: NIH Funding and the AATS

Author(s):  
John S. Ikonomidis
Keyword(s):  
2020 ◽  
pp. 1-9
Author(s):  
Russell R. Lonser ◽  
Luke G. F. Smith ◽  
Michael Tennekoon ◽  
Kavon P. Rezai-Zadeh ◽  
Jeffrey G. Ojemann ◽  
...  

OBJECTIVETo increase the number of independent National Institutes of Health (NIH)–funded neurosurgeons and to enhance neurosurgery research, the National Institute of Neurological Disorders and Stroke (NINDS) developed two national comprehensive programs (R25 [established 2009] for residents/fellows and K12 [2013] for early-career neurosurgical faculty) in consultation with neurosurgical leaders and academic departments to support in-training and early-career neurosurgeons. The authors assessed the effectiveness of these NINDS-initiated programs to increase the number of independent NIH-funded neurosurgeon-scientists and grow NIH neurosurgery research funding.METHODSNIH funding data for faculty and clinical department funding were derived from the NIH, academic departments, and Blue Ridge Institute of Medical Research databases from 2006 to 2019.RESULTSBetween 2009 and 2019, the NINDS R25 funded 87 neurosurgical residents. Fifty-three (61%) have completed the award and training, and 39 (74%) are in academic practice. Compared to neurosurgeons who did not receive R25 funding, R25 awardees were twice as successful (64% vs 31%) in obtaining K-series awards and received the K-series award in a significantly shorter period of time after training (25.2 ± 10.1 months vs 53.9 ± 23.0 months; p < 0.004). Between 2013 and 2019, the NINDS K12 has supported 19 neurosurgeons. Thirteen (68%) have finished their K12 support and all (100%) have applied for federal funding. Eleven (85%) have obtained major individual NIH grant support. Since the establishment of these two programs, the number of unique neurosurgeons supported by either individual (R01 or DP-series) or collaborative (U- or P-series) NIH grants increased from 36 to 82 (a 2.3-fold increase). Overall, NIH funding to clinical neurological surgery departments between 2006 and 2019 increased from $66.9 million to $157.3 million (a 2.2-fold increase).CONCLUSIONSTargeted research education and career development programs initiated by the NINDS led to a rapid and dramatic increase in the number of NIH-funded neurosurgeon-scientists and total NIH neurosurgery department funding.


Circulation ◽  
1995 ◽  
Vol 92 (3) ◽  
pp. 278-278 ◽  
Author(s):  
Claudia Louis ◽  
Scott Ballin
Keyword(s):  

Author(s):  
Karim ReFaey ◽  
William D. Freeman ◽  
Shashwat Tripathi ◽  
Hugo Guerrero-Cazares ◽  
Tiffany A. Eatz ◽  
...  
Keyword(s):  

2019 ◽  
Vol 42 (1) ◽  
pp. 57-60
Author(s):  
Kristine M. Kulage ◽  
Joshua R. Massei ◽  
Elaine L. Larson

Ordinal rankings of schools of nursing by research funding in total dollars awarded by the National Institutes of Health (NIH) is a common metric for demonstrating research productivity; however, these data are not based on the number of doctorally prepared faculty eligible to apply for funding. Therefore, we examined an alternative method for measuring research productivity which accounts for size differences in schools: NIH funding ranked “per capita.” We extracted data on total average funding and compared them with average funding secured per faculty member across top-ranked schools of nursing in the United States from 2013 to 2017. When examining data by number of doctorally prepared faculty, 4 of 12 (33%) schools that ranked lower in total average funding ranked higher in average funding per faculty member. School size is an important but neglected factor in current funding rankings; therefore, we encourage schools to use multiple approaches to track their research productivity.


2015 ◽  
Vol 19 (01) ◽  
pp. 47-53

A*STAR and GE Healthcare to improve healthcare outcomes through next generation innovations. Phylogica enters into research and licensing agreement with Genentech. FUJIFILM Completes Acquisition of Kalon Biotherapeutics. Bina Technologies acquired by Roche. ONO and Gilead enter exclusive license agreement to develop BTK inhibitor for the treatment of B-cell malignancies and other diseases. Uroplasty and Vision-Sciences to merge, creating medical device company. Amgen joins with LabCentral to support life-sciences and biotech startups in Cambridge. Temasek Life Sciences Laboratory appoints Prof Yu Hao as Executive Director. SomaGenics receives $2,275,000 in NIH funding to develop its RNAi Therapeutics and microRNA Technologies.


Sign in / Sign up

Export Citation Format

Share Document